Tvardi Therapeutics, Inc. Cash Flow-to-Debt Ratio
Tvardi Therapeutics, Inc. cash flow-to-debt ratio. Tvardi Therapeutics, Inc. (TVRD) has a Cash Flow-to-Debt Ratio of -1.01x as of June 2026, meaning its operating cash flow of $-9.23 Million could theoretically repay -1% of its total liabilities ($9.13 Million) in one year. Check Tvardi Therapeutics, Inc. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tvardi Therapeutics, Inc. (2020–2025)
Cash flow-to-debt ratio of Tvardi Therapeutics, Inc. from 2020 to 2025. Historical debt coverage capacity for Tvardi Therapeutics, Inc. across 6 annual periods. Also explore TVRD net asset momentum to track the company's year-over-year net asset growth rate.
Tvardi Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2020–2025)
Tvardi Therapeutics, Inc. cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Tvardi Therapeutics, Inc.. For the full cash flow conversion analysis, see TVRD cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.11x | $-23.50 Million | $11.13 Million | ▼ -67.9% |
| 2024 | -1.26x | $-60.92 Million | $48.42 Million | ▼ -21.7% |
| 2023 | -1.03x | $-92.08 Million | $89.06 Million | ▼ -421.7% |
| 2022 | -0.20x | $-17.87 Million | $90.15 Million | ▲ +93.6% |
| 2021 | -3.08x | $-60.09 Million | $19.53 Million | ▼ -1142.1% |
| 2020 | -0.25x | $-5.49 Million | $22.16 Million | — |